CN103463409A - Traditional Chinese medicine formula for treating heart qi deficiency - Google Patents
Traditional Chinese medicine formula for treating heart qi deficiency Download PDFInfo
- Publication number
- CN103463409A CN103463409A CN2013103649692A CN201310364969A CN103463409A CN 103463409 A CN103463409 A CN 103463409A CN 2013103649692 A CN2013103649692 A CN 2013103649692A CN 201310364969 A CN201310364969 A CN 201310364969A CN 103463409 A CN103463409 A CN 103463409A
- Authority
- CN
- China
- Prior art keywords
- parts
- mass fraction
- heart
- deficiency
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine formula, in particular to a traditional Chinese medicine formula for treating heart qi deficiency and aims to solve the technical problems that the existing medicine for treating the heart qi deficiency has a great side effect, cures the symptoms not the disease, is not scientific in compatibility and is bad in treatment effect. The traditional Chinese medicine formula for treating the heart qi deficiency comprises the following raw materials in parts by weight: 8-12 parts of white ginseng, 8-12 parts of cassia twig, 13-17 parts of mongolian snakegourd, 13-17 parts of allium macrostemon, 8-12 parts of rhizoma pinelliae preparata, 13-17 parts of root of common peony, 13-17 parts of radix ophiopogonis and 3-7 parts of coptis chinensis. The traditional Chinese medicine formula for treating the heart qi deficiency, disclosed by the invention, can effectively improve the cardiac function of a model rat suffering from the heart qi deficiency, promotes recovery of scathing cardiac muscle tissues, adjusts biochemical criterion, and has an excellent treatment effect on the model rat suffering from the heart qi deficiency; as proved by clinical trial, the traditional Chinese medicine formula has a total effective rate of more than 90% in treating the heart qi deficiency, is free from toxic and side effects, and is used in the field of treating heart qi deficiency syndrome.
Description
Technical field
The present invention relates to a kind of Chinese prescription.
Background technology
Syndrome of deficiency of heart qi is as one of clinical common pattern of syndrome of the thoracic obstruction, the serious threat mankind's health, be in recent years clinical focus feel concerned about syndrome.Syndrome of deficiency of heart qi caused by motive virtual loss, clinical with cardiopalmus, spontaneous perspiration, breathe hard, uncomfortable in chest, moving increase the weight of, spontaneous perspiration, the pallor light red tongue, deficient pulses etc. are common syndrome; From the modern medicine angle analysis, syndrome of deficiency of heart qi is similar to the cardiovascular disease of doctor trained in Western medicine, but not exclusively is equal to again it in terms of content.
At present the medicine for the treatment of syndrome of deficiency of heart qi usually have side effect large, cure the symptoms, not the disease, compatibility not science and the poor shortcoming of therapeutic effect, existing prescription design is this mainly with the deficiency of vital energy, blood stasis is target pathogenesis principle, medication be take Radix Ginseng, the Radix Astragali as main, QI invigorating rises to fall into and invigorates blood circulation with tonify deficiency, treated effect is 60～80%, and these prescriptions belong to clinical empirical summary, the research of the profound mechanism of shortage system more.
Summary of the invention
The objective of the invention is drug side effect in order to solve existing treatment syndrome of deficiency of heart qi large, cure the symptoms, not the disease, compatibility not science and the poor technical problem of therapeutic effect, and a kind of Chinese prescription for the treatment of insufficiency of heart-QI provided.
A kind of Chinese prescription for the treatment of insufficiency of heart-QI of the present invention, be comprised of the Radix Ginseng of 8～12 parts, the Ramulus Cinnamomi of 8～12 parts, the Fructus Trichosanthis of 13～17 parts, the Bulbus Allii Macrostemonis of 13～17 parts, the Rhizoma Pinelliae of 8～12 parts, the Radix Paeoniae Rubra of 13～17 parts, the Radix Ophiopogonis of 13～17 parts and the Rhizoma Coptidis of 3～7 parts by mass fraction.
Medical material effect in a kind of Chinese prescription for the treatment of insufficiency of heart-QI of the present invention is resolved as follows:
Sweet, the micro-hardship of monarch drug Radix Ginseng nature and flavor, tepor, return spleen lung, the heart, kidney channel.Function is strongly invigorating primordial QI, and multiple arteries and veins is admittedly de-, and invigorating the spleen to benefit the lung, promote the production of body fluid and nourish blood, the Fructus Alpiniae Oxyphyllae of calming the nerves; Be rich in Ginsenosides, ginseng polysaccharide, volatile oil, sterols and aminoacid, vitamin etc., wherein Ginsenosides is main active.Large quantity research shows, but ginsenoside's protecting myocardial cell reduces the blood pressure and blood lipoid level, resists myocardial ischemia.
Monarch drug Ramulus Cinnamomi nature and flavor acrid, sweet, warm.GUIXIN, lung, urinary bladder channel.Function is the diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.Contain a large amount of volatile oil in Ramulus Cinnamomi, take cinnamic aldehyde as main component, also comprise cinnamic acid, cinnamyl alcohol, syringic aldehyde, coumarin, 2-methoxybenzoic acid, protocatechuic acid etc.Also has in addition steroidal compounds as crossed cupreol, daucosterol, 5 α, 8 α-Ergosterol Peroxide etc.Research shows that the Ramulus Cinnamomi ethanol extraction has discharged vasodilator effect by suppressing the interior stream of calcium and calcium.Wherein syringic aldehyde and cinnamic acid can have antioxidant activity, and gastric mucosa injury is had to protective effect.
Ministerial drug Bulbus Allii Macrostemonis nature and flavor are hot, bitter, temperature.GUIXIN, lung, stomach, large intestine channel.Function is activating YANG and eliminating stagnation, the circulation of qi promoting intestinal stasis relieving.From the compound wherein separated, the compositions such as furostanol, volatile oil, nitrogen-containing compound, aminoacid are arranged, wherein Furost saponine is its main active, and what have now found that has macrostemonoside A, E, F, G, J, L, H, an I etc.Macrostemonoside can suppress human blood platelets activation and the gathering that adenosine diphosphate (ADP) (ADP) is induced, to the cytotoxic activity of different tumor cell lines.Macrostemonoside A can blood sugar lowering, can raise peroxisome proliferation-activated receptors γ and express, and increases the activity of lipase in visceral adipocytes and obesity, and the structure of its steroid has the effect of potential protection cardiovascular system.
Sweet, the micro-hardship of ministerial drug Fructus Trichosanthis nature and flavor, cold.Return lung, stomach, large intestine channel.Function is clearing away heat and eliminating phlegm, and relieving stuffiness of the chest by dispersing aggregation of pathogens, moisturize laxation.Contain abundant fatty oil in Semen Trichosanthis, the unsaturated fatty acids such as linolenic acid, Palmic acid, myristic acid, stearic acid, trichosanic acid are wherein arranged, and the pentacyclic triterpene such as sterol, karounidiol and cucurbitacine tetracyclic triterpene etc.Newspaper research report, unsaturated fatty acid can reduce triglyceride and mean arterial blood pressure, and in diet, the picked-up of unsaturated fatty acid can reduce the probability of suffering from cardiovascular disease.But linoleic acid can suppress macrophage adhesion activity atherosclerosis, reduce the serum low-density LP cholesterol levels, therefore reduced the incidence of coronary heart disease probability.
Ministerial drug Rhizoma Pinelliae nature and flavor suffering, temperature.Return spleen, stomach, lung meridian.Function is drying dampness to eliminate phlegm, for cough due to damp-phlegm, and the gastral cavilty feeling of fullness, the sputum cohesion, cough up and can not tell.Now from the Rhizoma Pinelliae, isolated main component has volatile oil, fatty acid, nucleoside, amino acid and protein etc.Wherein fatty acid be take the unsaturated fatty acids such as linoleic acid as main.Quantity research shows greatly, and the adenosine in nucleoside, can pass through specific adenosine receptor, and myocardial cell is had to direct protective effect, is also the active drug for the treatment of paroxysmal supraventricular tachycardia simultaneously.
Ministerial drug Radix Paeoniae Rubra nature and flavor hardship, be slightly cold.Return Liver Channel.Function is clearing away heat and cooling blood, eliminating stasis to stop pain.In isolated chemical composition, more with monoterpene and monoterpene glycosides content from Radix Paeoniae Rubra, be secondly triterpene and glycoside thereof, flavonoid, tannin class, sterols, organic acid and several amino acids and trace element.Monoterpene glycosides in Radix Paeoniae Rubra is usually by aromatic acid esterifications such as benzoic acid, P-hydroxybenzoic acid and gallic acids.Modern pharmacological research shows; peoniflorin suppresses the growth of human colon cancer cell; the Human Umbilical Vein Endothelial Cells apoptosis has protective effect; by alleviating the penetrating protection acute lung injury of inflammatory cell infiltration and blood capillary; its antiinflammatory action can reduce cerebral infarction and the neurologic impairment of ischemical reperfusion injury rat, the myocardial ischemia/reperfusion injury of cardioprotection.Gallic acid does not have cardioprotection entirely to the rat heart function of diabetes-induced, prevents the heart lysosome damage that isoproterenol causes.
Sweet, the micro-hardship of adjuvant drug nature and flavor Radix Ophiopogonis, be slightly cold.GUIXIN, lung, stomach warp.Function is YIN nourishing and the production of body fluid promoting, and lung moistening clears away heart-fire.Radix Ophiopogonis, main chemical compositions was steroidal saponin, polysaccharide and flavone compound.Got more than 40 kind of steroidal saponin from the Radix Ophiopogonis in difference source, as ophiopogonin B, C, D, E, F, G.Ophiopogonin and Radix Ophiopogonis polysaccharide have extensive prevention and cure of cardiovascular disease activity, and ophiopogonin D has protective effect to the human umbilical vein endothelial cell damage of hydrogen peroxide modeling, and Radix Ophiopogonis polysaccharide can resist myocardial ischemia.
Adjuvant drug Rhizoma Coptidis nature and flavor bitter cold, GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel.Heat clearing and damp drying, eliminating fire and detoxication.The effective ingredient of Rhizoma Coptidis is mainly multiple alkaloid, and wherein content of berberine is the highest.Berberine is remarkable in the pharmacological action of cardiovascular system, antiatherogenic effect may with regulate blood fat, inflammation-inhibiting, blood pressure lowering, blood sugar lowering, suppress vascular smooth muscle cell curing relevant; The arrhythmia of opposing II type rat diabetes myocardial infarction model; The cardiac toxicity that amycin in Mice Body is caused has protective effect; Lipid accumulation by alleviating heart and the Cardiac Function in Rat that promotes glucose transport protection hyperglycemia and hypercholesterolemia to bring out are incomplete; Can effectively regulate the sympathetic activity of experimental rat cardiac hypertrophy, there are treatment myocardial hypertrophy and chronic heart failure patient's potentiality.
Take Radix Ginseng, Ramulus Cinnamomi in side is monarch drug temperature compensation yang-energy, warming the meridian and promoting blood circulation; Fructus Trichosanthis, Bulbus Allii Macrostemonis, the Rhizoma Pinelliae the chest stuffiness relieving of regulating the flow of vital energy, the clearing away phlegm eliminating stagnation of activating yang, be equipped with the Radix Paeoniae Rubra promoting flow of QI and blood, makes the perfect square tonify without causing stagnation; For a long time easy impairment of YIN for the product of warm-dryness syndrome, therefore, with Radix Ophiopogonis, Rhizoma Coptidis is helped it, the Rhizoma Coptidis heat clearing away, moisturize YIN nourishing Radix Ophiopogonis.
The present invention has following beneficial effect:
One, a kind of Chinese prescription for the treatment of insufficiency of heart-QI of the present invention, can obviously improve weak, the lazy moving state of rat model and left ventricular contraction, diastolic function, and indivedual indexs are better than the blank group; More obvious to the improvement of MDA content, SOD activity in biochemical indicator, difference has significant, and high dose group slightly is better than low dose group and natural recovering group to the improvement of cAMP, cGMP, ANF, cTn-I, but difference is many without significant.Cardiomyopathy is of science, Change of Ultrastructure shows, with natural recovering group, compares, and the myocardium cell injuring degree of administration group rat obviously improves, and it is basically identical that high dose group and low dose group are improved degree.Comprehensive each index judgement, this prescription has therapeutical effect preferably to the insufficiency of heart-QI rat model, and this prescription high dose group curative effect is better than low dose group, and low dose group is better than natural recovering group, and the prompting prescription has the positive vector effect relationship.
Two, a kind of state of an illness for the treatment of the Chinese prescription design considerations deficiency in origin and excess in superficiality of insufficiency of heart-QI of the present invention, along with social development, the variation of environment, the change of dietary habit, the pathogenesis feature of insufficiency of heart-QI is to take atmospheric subsidence as this, the mutual resistance of the expectorant stasis of blood is mark.Select the Radix Ginseng strongly invigorating primordial QI in side, but reinforcing the heart gas, the gas controlling blood and vessel, the prosperous blood of gas, the thoracic obstruction can be dispelled: be aided with the Ramulus Cinnamomi promoting the flow of QI-blood by warming the meridian, supporing yang activating QI; The Bulbus Allii Macrostemonis warming middle-JIAO activates yang, therapeutic method to keep the adverse QI flowing downwards eliminating stagnation; With Rhizoma Pinelliae drying dampness to eliminate phlegm, dissolving lump and resolving mass, Fructus Trichosanthis is led expectorant promoting the circulation of QI relieving accumulation of pathogens again, with the pain relieving of Radix Paeoniae Rubra promoting blood circulation to remove blood stasis, and of a specified duration easily impairment of YIN for the product of warm-dryness syndrome, assistant is with Rhizoma Coptidis to stop up clearly heat, and Radix Ophiopogonis is nourshing Yin and drynsessmoistening prescription, and play altogether and take the effect that the warming YANG benefit heart, phlegm reduction of blood circulation promoting be the master full side.
Three, a kind of Chinese prescription for the treatment of insufficiency of heart-QI of the present invention, focus on the relation of the integrally-regulated and QI and blood of human body, improve the adaptation state of body to internal and external environment variation, destructive stimulus, with the coordinating YIN and YANG QI and blood, making it to set up new balance is therapeutic purposes, righting and eliminating evil developing simultaneously, take stopgap measures and effect a permanent cure with executing; And the prescription Chinese crude drug is easy to get, each medical material all has no side effect, and long-term taking can not damage internal organs yet, and drug dependence is less, and medication is safer.
Four, a kind of Chinese prescription for the treatment of insufficiency of heart-QI of the present invention, to the syndrome of deficiency of heart qi determined curative effect, can effectively eliminate spontaneous perspiration, cardiopalmus, breathe hard, the common disease of uncomfortable in chest, pallor light red tongue and deficient pulse, and total effective rate is more than 90%.
The accompanying drawing explanation
Fig. 1 respectively organizes the rat body weight variation diagram during the Treated with Chinese Decoction in embodiment mono-; In figure, 1 is blank group, and 2 is low dose group, and 3 is natural recovering group, and 4 is high dose group;
Fig. 2 is the intrinsic pressure figure of blank group rat cardiac ventricular in embodiment mono-;
Fig. 3 is the intrinsic pressure figure of natural recovering group rat cardiac ventricular in embodiment mono-;
Fig. 4 is the intrinsic pressure figure of high dose group rat cardiac ventricular in embodiment mono-;
Fig. 5 is the intrinsic pressure figure of low dose group rat cardiac ventricular in embodiment mono-;
The form microscopy figure of heart cardiac muscular tissue that Fig. 6 is the normal rat in embodiment mono-;
The muscle fiber microscopy figure that Fig. 7 is the natural recovering group rat heart in embodiment mono-;
The interstitial blood capillary microscopy figure that Fig. 8 is the natural recovering group rat heart in embodiment mono-;
The interstitial microscopy figure that Fig. 9 is the natural recovering group rat heart in embodiment mono-;
Figure 10 is the natural recovering group rat heart microscopy figure in embodiment mono-;
The tissue morphology microscopy figure that Figure 11 is the high dose group rat heart in embodiment mono-
The blood capillary microscopy figure that Figure 12 is the high dose group rat heart in embodiment mono-;
The interstitial microscopy figure that Figure 13 is the high dose group rat heart in embodiment mono-;
The blood capillary microscopy figure that Figure 14 is the high dose group rat heart in embodiment mono-;
The interstitial microscopy figure that Figure 15 is the low dose group rat heart in embodiment mono-;
The tissue morphology microscopy figure that Figure 16 is the low dose group rat heart in embodiment mono-;
The blood capillary microscopy figure that Figure 17 is the low dose group rat heart in embodiment mono-;
The interstitial microscopy figure that Figure 18 is the low dose group rat heart in embodiment mono-;
Figure 19 is that the blank group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 6000 times;
Figure 20 is that the blank group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 11500 times;
Figure 21 is that the natural recovering group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 6000 times;
Figure 22 is that the natural recovering group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 11500 times;
Figure 23 is that the high dose group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 6000 times;
Figure 24 is that the high dose group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 11500 times;
Figure 25 is that the low dose group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 6000 times;
Figure 26 is that the low dose group rat in embodiment mono-is amplified the myocardial ultrastructure figure of 11500 times.
The specific embodiment
Technical solution of the present invention is not limited to the following cited specific embodiment, also comprises the combination in any between each specific embodiment.
The specific embodiment one: the Chinese prescription that present embodiment is a kind of treats insufficiency of heart-QI is comprised of the raw material of following mass fraction: the Radix Ginseng of 8～12 parts, the Ramulus Cinnamomi of 8～12 parts, the Fructus Trichosanthis of 13～17 parts, the Bulbus Allii Macrostemonis of 13～17 parts, the Rhizoma Pinelliae of 8～12 parts, the Radix Paeoniae Rubra of 13～17 parts, the Radix Ophiopogonis of 13～17 parts and the Rhizoma Coptidis of 3～7 parts.
After a kind of Chinese prescription for the treatment of insufficiency of heart-QI of present embodiment is made dry powder, can add pharmaceutic adjuvant, be prepared into capsule, tablet, granule, electuary, oral liquid, buccal tablet or powder and take for the patient, the preparation method of the dry powder (hereinafter referred to as Wen Xinfang) of the Chinese prescription extract of described treatment insufficiency of heart-QI is as follows:
One, get the Radix Ginseng of 8～12 parts, the Ramulus Cinnamomi of 8～12 parts, the Fructus Trichosanthis of 13～17 parts, the Bulbus Allii Macrostemonis of 13～17 parts, the Rhizoma Pinelliae of 8～12 parts, the Radix Paeoniae Rubra of 13～17 parts, the Radix Ophiopogonis of 13～17 parts and the Rhizoma Coptidis of 3～7 parts, add the ethanol that the mass concentration that accounts for 8 times of amounts of said medicine gross mass is 70%, then reflux, extract, is 3 times, each 1～2 hour, merge extractive liquid, cooling 10～15min, then through 16 layers of filtered through gauze;
Two, add the ethanol that the mass concentration that accounts for 8 times of amounts of filtering residue gross mass is 70% in the filtering residue after filtering to step 1, reflux, extract, 1 hour, cooling 10～the 15min of extracting solution, then through 16 layers of filtered through gauze, filtering residue after filtration adds the ethanol that the mass concentration that accounts for 8 times of amounts of filtering residue quality is 70% again, reflux, extract, 1 hour, all filtrate in combining step one and step 2, reclaim under reduced pressure filtrate, be concentrated into without the alcohol flavor, then proceed in evaporating dish 70 ℃ of heating in water bath evaporates to dryness, then be placed in vacuum drying oven dry, complete the preparation of Wen Xinfang.
The usage and dosage of Wen Xinfang in present embodiment: adult every day 2 times, a 9-13g, 4 weeks be a course for the treatment of.
The specific embodiment two: present embodiment is different from the specific embodiment one: the mass fraction of described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, the mass fraction of Rhizoma Pinelliae is 8～12 parts, the mass fraction of Radix Paeoniae Rubra is 13～17 parts, and the mass fraction of Radix Ophiopogonis is 13～17 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts, and other is identical with the specific embodiment one.
The specific embodiment three: present embodiment is different from the specific embodiment one or two: the mass fraction of described Radix Ginseng is 8～12 parts, the mass fraction of Ramulus Cinnamomi is 8～12 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, the mass fraction of Rhizoma Pinelliae is 8～12 parts, the mass fraction of Radix Paeoniae Rubra is 13～17 parts, and the mass fraction of Radix Ophiopogonis is 13～17 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.Other is identical with the specific embodiment one or two.
The specific embodiment four: present embodiment is different from one of specific embodiment one to three: the mass fraction of described Radix Ginseng is 8～12 parts, the mass fraction of Ramulus Cinnamomi is 8～12 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, the mass fraction of Rhizoma Pinelliae is 8～12 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.Other is identical with one of specific embodiment one to three.
The specific embodiment five: present embodiment is different from one of specific embodiment one to four: the mass fraction of described Radix Ginseng is 8～12 parts, the mass fraction of Ramulus Cinnamomi is 8～12 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, the mass fraction of Rhizoma Pinelliae is 8～12 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.Other is identical with one of specific embodiment one to four.
The specific embodiment six: present embodiment is different from one of specific embodiment one to five: the mass fraction of described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, the mass fraction of Rhizoma Pinelliae is 9～11 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.Other is identical with one of specific embodiment one to five.
The specific embodiment seven: present embodiment is different from one of specific embodiment one to six: the mass fraction of described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, the mass fraction of Rhizoma Pinelliae is 8～12 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.Other is identical with one of specific embodiment one to six.
The specific embodiment eight: present embodiment is different from one of specific embodiment one to seven: the mass fraction of described Radix Ginseng is 10 parts, the mass fraction of Ramulus Cinnamomi is 10 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, the mass fraction of Rhizoma Pinelliae is 8～12 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.Other is identical with one of specific embodiment one to seven.
The specific embodiment nine: present embodiment is different from one of specific embodiment one to eight: the mass fraction of described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 15 parts, the mass fraction of Bulbus Allii Macrostemonis is 15 parts, the mass fraction of Rhizoma Pinelliae is 10 parts, the mass fraction of Radix Paeoniae Rubra is 15 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.Other is identical with one of specific embodiment one to eight.
The specific embodiment ten: present embodiment is different from one of specific embodiment one to nine: the mass fraction of described Radix Ginseng is 10 parts, the mass fraction of Ramulus Cinnamomi is 10 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, the mass fraction of Rhizoma Pinelliae is 9～11 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 15 parts, and the mass fraction of Rhizoma Coptidis is 5 parts.Other is identical with one of specific embodiment one to nine.
The specific embodiment 11: present embodiment is different from one of specific embodiment one to ten: the mass fraction of described Radix Ginseng is 10 parts, the mass fraction of Ramulus Cinnamomi is 10 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, the mass fraction of Rhizoma Pinelliae is 9～11 parts, the mass fraction of Radix Paeoniae Rubra is 15 parts, and the mass fraction of Radix Ophiopogonis is 15 parts, and the mass fraction of Rhizoma Coptidis is 5 parts.Other is identical with one of specific embodiment one to ten.
The specific embodiment 12: present embodiment is different from one of specific embodiment one to 11: the mass fraction of described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 15 parts, the mass fraction of Bulbus Allii Macrostemonis is 15 parts, the mass fraction of Rhizoma Pinelliae is 10 parts, the mass fraction of Radix Paeoniae Rubra is 14～16 parts, and the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.Other is identical with one of specific embodiment one to 11.
Adopt following examples and contrast test to verify beneficial effect of the present invention:
Embodiment mono-:
The present embodiment is used the dry powder (hereinafter referred to as Wen Xinfang) of the Chinese prescription extract for the treatment of insufficiency of heart-QI to carry out demonstration test, and the preparation method of Wen Xinfang is specifically carried out according to the following steps:
One, get 10g Radix Ginseng, 10g Ramulus Cinnamomi, 15g Fructus Trichosanthis, 15g Bulbus Allii Macrostemonis, 10g Rhizoma Pinelliae, 15g Radix Paeoniae Rubra, 15g Radix Ophiopogonis and 5g Rhizoma Coptidis, add the ethanol that the mass concentration that accounts for 8 times of amounts of said medicine gross mass is 70%, then reflux, extract, is 3 times, each 1～2 hour, merge extractive liquid, cooling 10～15min, then through 16 layers of filtered through gauze;
Two, add the ethanol that the mass concentration that accounts for 8 times of amounts of filtering residue gross mass is 70% in the filtering residue after filtering to step 1, reflux, extract, 1 hour, cooling 10～the 15min of extracting solution, then through 16 layers of filtered through gauze, filtering residue after filtration adds the ethanol that the mass concentration that accounts for 8 times of amounts of filtering residue quality is 70% again, reflux, extract, 1 hour, all filtrate in combining step one and step 2, reclaim under reduced pressure filtrate, be concentrated into without the alcohol flavor, then proceed in evaporating dish 70 ℃ of heating in water bath evaporates to dryness, then be placed in vacuum drying oven dry, complete the preparation of Wen Xinfang.
The demonstration test step is as follows:
One, 64 rats are divided into to four groups at random, 16 every group, are respectively: blank group, natural recovering group, high dose group and low dose group; Wherein, natural recovering group, high dose group and low dose group are the modeling group;
Two, 1st～21 days, modeling group rat was set up the insufficiency of heart-QI model, blank group rat feeding every day Mus grain 30g; 22nd～35 days, high dose group gavages Wen Xinfang medicinal liquid 1.0ml/100g(by body weight and give crude drug 3.42g/100g every day), it is that low dosage gives crude drug 0.855g/100g that low dose group gavages Wen Xinfang medicinal liquid 1.0ml/100g(by body weight every day), the every daily weight 1.0ml/100g of natural recovering group and blank group gavages normal saline, respectively organizes rat and all gives 30g Mus grain simultaneously;
Three, within the 36th day, respectively organize rat and carry out index determining.Each organizes rat since 6:00 collection the 1st day morning 12h urine at night, every 1 day, collects 1 time.Urine in pvc pipe, 13000r/min, 4 ℃ of centrifugal 10min, get supernatant, puts in-20 ℃ of refrigerators and to preserve standby inspection.
Result of the test is as follows:
1. the impact of Chinese prescription on the rat sign
Blank group rat is submissive smooth at whole experimental session chaeta, is quick on the draw.All the other each groups after duplicating model success, show weak weak, weak breath lazy moving, the nose color is light, hair dries up, rare soft, state of looking for food of defecating.The 22nd day (being administration the 1st day) starts, and each is organized the rat state and all recovers to some extent, and the weak state of this prescription high dose group is eliminated very fast, within the 24th day, shows more active.The 32nd day (being administration the 11st day) respectively organizes the mental status, the skin and hair of rat, the undesirable condition of nose color all is clearly better, and the rat of high dose group and low dose group is more active than natural recovering group and blank group.The rat of the 35th day (being administration the 14th day) this prescription high dose group and low dose group is more pink than the nose color of natural recovering group.
2. the impact of Chinese prescription on rat body weight
When modeling finishes, blank group rat body weight is 325.6 ± 14.6g, and the natural recovering group rat body weight is 193.3 ± 5.9g, and this prescription high dose group rat body weight is 193.1 ± 9.6g, and this prescription low dose group rat body weight is 198.5 ± 13.4g, as shown in Figure 1.After entering treatment/convalescent period, with the blank group relatively each modeling group rat body weight all have faster and to increase, group difference is without significant, but finishes each modeling group rat body weight still lower than blank group to laboratory, difference has significant.
3. the impact of Chinese prescription on the rat cardiac ventricular hemodynamic index
With the natural recovering group rat, compare, administration group rat heart rate is faster, and wherein the difference of low dose group has significant, with the blank group, compares, and it is still slower that each organizes rat heart rate, and difference has significant.With the natural recovering group rat, compare, administration group left ventricle maximum collapse is pressed and is obviously increased, and wherein the difference of high dose group has significant; With the blank group, compare, administration group ventricle maximum internal pressure is also higher, but no significant difference.With natural recovering group, compare, the most careful intraventricular pressure of administration group obviously reduces, and wherein the difference of high dose group has statistical significance.The maximum climbing speed of the systolic pressure of administration group and the maximum fall off rate absolute value of diastolic pressure all have and increase, and obviously surpass natural recovering group and blank group, and difference has statistical significance.As shown in Fig. 2, Fig. 3, Fig. 4, Fig. 5 and table 1.
Table 1 Chinese prescription is to insufficiency of heart-QI rat model ventricle hemodynamic effects (Mean+SD)
Annotate: with the blank group, compare * P ﹤ 0.05, * * P ﹤ 0.01; With natural recovering group comparison ▲ P ﹤ 0.05, ▲ ▲ P ﹤ 0.01.
4. the impact of Chinese prescription on the rat biochemical indicator
4.1 cyclic adenosine monophosphate cAMP and cyclic guanosine monophosphate cGMP changes of contents
As shown in table 2, after treatment, the cAMP in this prescription high dose, low dosage and natural recovering group rat plasma and cGMP content all increase to some extent, compare no significant difference with the blank group.
Table 2 Chinese prescription is to insufficiency of heart-QI rat model plasma cAMP, cGMP content influence (Mean+SD)
4.2 atrial natriuretic peptide ANF changes of contents
As shown in table 3, after treatment, this prescription high dose group rat plasma ANF content increases, and with natural recovering group, compares, and difference has significant; High dose group and low dose group and blank group compare, no significant difference.
4.3 myocardium calcium cTn-I changes of contents
As shown in table 3, after treatment, this prescription high dose group and low dose group rat plasma cTn-I content descend, but compare no significant difference with natural recovering group; High dose group and low dose group and blank group compare, no significant difference.
Table 3 Chinese prescription is to insufficiency of heart-QI rat model plasma ANF, cTn-I content influence (Mean+SD)
Annotate: with natural recovering group comparison ▲ P ﹤ 0.05.
4.4 lipid peroxide MDA content and SOD activity change
As shown in table 4, after treatment, this prescription high dose group and low dose group Content of MDA descend, and with natural recovering group, compare, and difference has significant; The SOD activity increases, and with natural recovering group, compares, and difference has significant; High dose group MDA content is lower than blank group, and difference has significant; Natural recovering group SOD vigor is lower than blank group, and difference has significant.
The important prescription of table 4 is to insufficiency of heart-QI rat model serum MDA, SOD content influence (Mean+SD)
Annotate: compare * P<0.05, * * P<0.01 with the blank group; With natural recovering group, compare, ▲ P ﹤ 0.05, ▲ ▲ P ﹤ 0.01.
5. to the rat heart muscle pathological effect
With the heart cardiac muscular tissue (as shown in Figure 6) of normal rat, to compare natural recovering group rat heart microscopy normal, and volume etc. are large, smooth surface, and each room, cell structure are normal, high-visible; Microscopy visible part muscle fiber atrophy, swelling, vasodilation hyperemia between part flesh, visible kitchen range myolysis, as shown in Figure 7 to 10.After treating, this prescription high dose group, low dose group rat heart organizational structure are recovered better, and it is comparatively neat that under mirror, visible muscle fiber is the bundle arrangement, and nucleus is complete, but the slight hyperemia of visible part blood vessel and a small amount of interstitial edema, as shown in Figure 11 to Figure 18.
6. on the impact of myocardial ultrastructure
Compare the broadening of the visible fiber myofilament of natural recovering group myocardial ultrastructure intercalated disc with the myocardial ultrastructure (as shown in Figure 19, Figure 20) of blank group rat, the partial line Mitochondria Membrane is damaged, dissolving, the ridge disorder, visible endoplasmic reticulum is vacuolation, as shown in Figure 21, Figure 22.After this prescription therapeutic, high dose group, low dose group myocardial ultrastructure make moderate progress, and visible cardiac muscle fiber is arranged comparatively neat, each band of muscle segment is comparatively clear, and mitochondrion peplos is comparatively complete, and the endoplasmic reticulum cavity is less, and high dose group is better than low dose group, as shown in Figure 23 to Figure 26.
Embodiment bis-,
In order to show a kind of therapeutic effect of the Chinese prescription of insufficiency of heart-QI to motive deficient syndrome patient for the treatment of of the present invention, adopt the Wen Xinfang of preparation in embodiment 1 to carry out the system clinical observation treatment to 98 routine insufficiency of heart-QI patients, medical history, the state of an illness and curative effect to above-mentioned patient in the process of above-mentioned clinical observation are carried out record.
The clinical therapeutic efficacy criterion is:
Cure: common sign as spontaneous perspiration, cardiopalmus, breathe hard, uncomfortable in chest, movingly increase the weight of, the pallor light red tongue, deficient pulse all disappears.
Take a turn for the better: subjective symptoms as cardiopalmus, breathe hard, uncomfortable in chest, spontaneous perspiration disappears substantially, it is normal that complexion and pulse condition are tending towards.
Invalid: symptom, sign are not improved.
Therapeutic effect: a kind of Chinese prescription for the treatment of insufficiency of heart-QI of the present invention is treated through 98 routine motive deficient syndrome patients, 79 example recoveries from illness, and 10 examples take a turn for the better, and 9 examples are invalid, and total effective rate reaches 90.8%.
Model case:
Case 1: patient Liu, the female, 47 years old, suffer from motive deficient syndrome 2 years, long-term cardiopalmus, breathe hard, uncomfortable in chest, pale complexion, take Chinese medicine of the present invention after 5 months, symptom disappears fully, pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 2: patient Lee, the female, 52 years old, suffer from motive deficient syndrome 3 years, long-term discomfort uncomfortable in chest, shortness of breath and fatigue, more so, take Chinese medicine of the present invention after 6 months after activity, and symptom disappears fully, and pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 3: patient Zhang, the female, 34 years old, suffer from syndrome of deficiency of heart qi, conscious severe palpitation, took Chinese medicine of the present invention after 2 months, and symptom disappears fully, and pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 4: the patient is in so-and-so, the man, and 58 years old, suffer from syndrome of deficiency of heart qi 1 year, long-term discomfort uncomfortable in chest, shortness of breath and fatigue, Mental fatigue spontaneous perspiration, took Chinese medicine of the present invention after 6 months, and symptom disappears fully, and pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 5: patient Zhang, the female, 48 years old, suffer from motive deficient syndrome 2 years, long-term discomfort uncomfortable in chest, shortness of breath and fatigue, Mental fatigue spontaneous perspiration, multi-treatment is invalid, takes Chinese medicine of the present invention after 7 months, and symptom disappears fully, and pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 6: patient Pan so-and-so, the female, 46 years old, suffer from syndrome of deficiency of heart qi, cardiopalmus, breathe hard, pale tongue with thin fur, take Chinese medicine of the present invention after 2 months, symptom disappears fully, pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 7: patient Yang, the female, 52 years old, suffer from syndrome of deficiency of heart qi 1 year, for a long time uncomfortable in chest, breathe hard, take Chinese medicine of the present invention after 5 months, symptom disappears fully, pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Case 8: patient Lin, the man, 53 years old, suffer from syndrome of deficiency of heart qi, discomfort uncomfortable in chest, shortness of breath and fatigue, more so, take Chinese medicine of the present invention after 4 months after activity, and symptom disappears fully, and pulse condition is normal, follows up a case by regular visits to not recurrence in a year.
Claims (10)
1. a Chinese prescription for the treatment of insufficiency of heart-QI, is characterized in that what a kind of Chinese prescription for the treatment of insufficiency of heart-QI was comprised of the raw material of following mass fraction: the Radix Ginseng of 8～12 parts, the Ramulus Cinnamomi of 8～12 parts, the Fructus Trichosanthis of 13～17 parts, the Bulbus Allii Macrostemonis of 13～17 parts, the Rhizoma Pinelliae of 8～12 parts, the Radix Paeoniae Rubra of 13～17 parts, the Radix Ophiopogonis of 13～17 parts and the Rhizoma Coptidis of 3～7 parts.
2. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, and the mass fraction of Rhizoma Pinelliae is 8～12 parts, and the mass fraction of Radix Paeoniae Rubra is 13～17 parts, the mass fraction of Radix Ophiopogonis is 13～17 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.
3. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 8～12 parts, the mass fraction of Ramulus Cinnamomi is 8～12 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, and the mass fraction of Rhizoma Pinelliae is 8～12 parts, and the mass fraction of Radix Paeoniae Rubra is 13～17 parts, the mass fraction of Radix Ophiopogonis is 13～17 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.
4. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 8～12 parts, the mass fraction of Ramulus Cinnamomi is 8～12 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, and the mass fraction of Rhizoma Pinelliae is 8～12 parts, and the mass fraction of Radix Paeoniae Rubra is 14～16 parts, the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.
5. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 8～12 parts, the mass fraction of Ramulus Cinnamomi is 8～12 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, and the mass fraction of Rhizoma Pinelliae is 8～12 parts, and the mass fraction of Radix Paeoniae Rubra is 14～16 parts, the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.
6. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, and the mass fraction of Rhizoma Pinelliae is 9～11 parts, and the mass fraction of Radix Paeoniae Rubra is 14～16 parts, the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.
7. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 13～17 parts, the mass fraction of Bulbus Allii Macrostemonis is 13～17 parts, and the mass fraction of Rhizoma Pinelliae is 8～12 parts, and the mass fraction of Radix Paeoniae Rubra is 14～16 parts, the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.
8. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 10 parts, the mass fraction of Ramulus Cinnamomi is 10 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, and the mass fraction of Rhizoma Pinelliae is 8～12 parts, and the mass fraction of Radix Paeoniae Rubra is 14～16 parts, the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 3～7 parts.
9. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 9～11 parts, the mass fraction of Ramulus Cinnamomi is 9～11 parts, the mass fraction of Fructus Trichosanthis is 15 parts, the mass fraction of Bulbus Allii Macrostemonis is 15 parts, and the mass fraction of Rhizoma Pinelliae is 10 parts, and the mass fraction of Radix Paeoniae Rubra is 15 parts, the mass fraction of Radix Ophiopogonis is 14～16 parts, and the mass fraction of Rhizoma Coptidis is 4～6 parts.
10. a kind of Chinese prescription for the treatment of insufficiency of heart-QI according to claim 1, the mass fraction that it is characterized in that described Radix Ginseng is 10 parts, the mass fraction of Ramulus Cinnamomi is 10 parts, the mass fraction of Fructus Trichosanthis is 14～16 parts, the mass fraction of Bulbus Allii Macrostemonis is 14～16 parts, and the mass fraction of Rhizoma Pinelliae is 9～11 parts, and the mass fraction of Radix Paeoniae Rubra is 14～16 parts, the mass fraction of Radix Ophiopogonis is 15 parts, and the mass fraction of Rhizoma Coptidis is 5 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310364969.2A CN103463409B (en) | 2013-08-20 | 2013-08-20 | Traditional Chinese medicine formula for treating heart qi deficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310364969.2A CN103463409B (en) | 2013-08-20 | 2013-08-20 | Traditional Chinese medicine formula for treating heart qi deficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463409A true CN103463409A (en) | 2013-12-25 |
| CN103463409B CN103463409B (en) | 2015-06-17 |
Family
ID=49788601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310364969.2A Active CN103463409B (en) | 2013-08-20 | 2013-08-20 | Traditional Chinese medicine formula for treating heart qi deficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463409B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816494A (en) * | 2014-03-21 | 2014-05-28 | 王建蓉 | Traditional Chinese medicine composition for treating deficiency of heart-qi |
| CN104101674A (en) * | 2014-05-16 | 2014-10-15 | 王喜军 | Pharmacodynamic material basis screening method of artemisia capillaries soup |
| CN104667174A (en) * | 2015-02-03 | 2015-06-03 | 辽宁中医药大学 | Liquid capsule for treating coronary heart disease with yang deficiency and blood stasis and preparation method of liquid capsule |
| CN106389823A (en) * | 2016-11-11 | 2017-02-15 | 东莞市百替生物科技有限公司 | Traditional Chinese medicine preparation for curing insufficiency of heart qi and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101841A (en) * | 1993-10-18 | 1995-04-26 | 淄博市中医院 | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof |
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1425441A (en) * | 2002-12-31 | 2003-06-25 | 南京中医药大学附属医院 | Compound macrostem onion preparation for curing chronic obstructive lung disease and its preparing method |
| CN101829268A (en) * | 2009-03-09 | 2010-09-15 | 丁卫华 | Numbness relieving and heart-soothing medicinal wine |
-
2013
- 2013-08-20 CN CN201310364969.2A patent/CN103463409B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101841A (en) * | 1993-10-18 | 1995-04-26 | 淄博市中医院 | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof |
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1425441A (en) * | 2002-12-31 | 2003-06-25 | 南京中医药大学附属医院 | Compound macrostem onion preparation for curing chronic obstructive lung disease and its preparing method |
| CN101829268A (en) * | 2009-03-09 | 2010-09-15 | 丁卫华 | Numbness relieving and heart-soothing medicinal wine |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816494A (en) * | 2014-03-21 | 2014-05-28 | 王建蓉 | Traditional Chinese medicine composition for treating deficiency of heart-qi |
| CN104101674A (en) * | 2014-05-16 | 2014-10-15 | 王喜军 | Pharmacodynamic material basis screening method of artemisia capillaries soup |
| CN104101674B (en) * | 2014-05-16 | 2016-05-04 | 王喜军 | A kind of method of screening Yinchenhao Tang, Oriental Wormwood Decoction effective substance |
| CN104667174A (en) * | 2015-02-03 | 2015-06-03 | 辽宁中医药大学 | Liquid capsule for treating coronary heart disease with yang deficiency and blood stasis and preparation method of liquid capsule |
| CN104667174B (en) * | 2015-02-03 | 2018-02-06 | 辽宁中医药大学 | A kind of iquid capsule for treating coronary heart disease syndrome of yang deficiency and blood stasis and preparation method thereof |
| CN106389823A (en) * | 2016-11-11 | 2017-02-15 | 东莞市百替生物科技有限公司 | Traditional Chinese medicine preparation for curing insufficiency of heart qi and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463409B (en) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1742939B (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN104758806A (en) | Decocted extract for treating coronary heart disease and preparation method thereof | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN103749824B (en) | A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN105343466A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN104107348A (en) | Chinese herbal medicine for blood sugar reducing, and administration method thereof | |
| CN103463464A (en) | Health care medicinal wine | |
| CN104707004A (en) | Medicine capable of reducing blood pressure | |
| CN101757408A (en) | Medicament for treating lupus erythematosus and preparation method thereof | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN103432377B (en) | Preparation method of Wenxin Formulation | |
| CN102631607B (en) | Medicament for treating cardiovascular diseases and preparation method thereof | |
| CN105232677A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition | |
| CN104117020A (en) | Traditional Chinese medicinal formula for treating atrial fibrillation | |
| CN103656196A (en) | Traditional Chinese medicine composition for treating cutaneous pruritus caused by diabetes and preparation method thereof | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |